Мерцательная аритмия у больных хронической обструктивной болезнью легких ассоциирована со структурными изменениями миокарда, но не с биомаркерами фиброза
Е.А. Волчкова
А.Г. Никитин
Н.Е. Резниченко
А.А. Затейщикова
И.В. Шаврин
В.И. Сафарян
В.В. Носиков
Д.А. Затейщиков
PDF

Ключевые слова

биомаркеры фиброза
хроническая обструктивная болезнь лёгких
мерцательная аритмия
fibrosis biomarkers
chronic obstructive pulmonary disease (COPD)
atrial fibrillation.

Как цитировать

[1]
.
PDF

Аннотация

Имеются данные об изменении вегетативного баланса в сторону преобладания симпатических влияний у боль-ных с МА.Цель исследования – выявление ассоциации уровня TGF- E1в сыворотке крови и его генетического полиморфизма с развитием МА у больных ХОБЛ. Материалы и методы: обследовано 167 больных ХОБЛ (44 с МА и 123 без МА). Всем больным проводили определение уровня TGF-E1 в сыворотке, изучение частоты полиморфного маркёра rs1800471(Arg25Pro) гена TGF- E1, спирометрию, Эхо-КГ. Результаты: не выявлено взаимосвязи развития МА у больных ХОБЛ с изменением концентрацией TGF-E 1 в сыворотке и полиморфизмом rs1800471(Arg25Pro) гена TGF- E1.  Вывод: у больных с тяжелым течением ХОБЛ высокой активности процессов фиброза оказывается недостаточно для развития МА Backgrounds: There are findings which show a vegetative balance shift to sympathetic effects in patients with atrial fibril-lation (AF). Aim: To reveal associations of TGF-E1 levels in blood serum and its genetic polymorphisms with AF progressingin patients with chronic obstructive pulmonary disease (COPD). Materials and methods: 167 with COPD were examined ( 44patients with AF and 123 patients without AF). Inall patients TGF-E1 levels in serum, rate of polymorphic marker rs1800471(Arg25Pro) of gene TGF-E1 , spirometry and echocardiography data were studied. Results: There were no associationrevealed between AF development in patients with COPD and changes of TGF-E1 concentration in the serum and polymor-phism rs1800471 (Arg25Pro) of gene TGF-E1. Conclusion: In patients with severe COPD forms a high fibrosis activity isnot enough for developing AF.
PDF

Литература

1. Fuster V., Rydˆen L.E., Cannom D.S. et al. 2011
ACCF/AHA/HRS focused updates incorporated into the
ACC/AHA/ESC 2006 Guidelines for the management of p
a-
tients with atrial fibrillation: a report of the Am
erican Col-
lege of Cardiology Foundation/American Heart Associ
ation
Task Force on Practice Guidelines developed in par
tnership
with the European Society of Cardiology and in coll
aboration
with the European Heart Rhythm Association and the
Heart
Rhythm Society. Journal of the American College of
Cardiol-
ogy. 2011; 57(11): e101-e198.
2. Murray C.J.L/, AD. L: Evidence-based health poli
-
cy lessons from the Global Burden of Disease study.
Science.
1996; 274: 740-743.
3. Kleiger R.E., Senior R.M.: Longterm electrocar-
diographic monitoring of ambulatory patients with c
hronic
airway-obstruction. Chest. 1974; 65(5): 483-487.
4. Ihn H. Pathogenesis of fibrosis: role of TGF-
E
and
CTGF. Curren t opinion in rheumatology. 2002; 14(6)
: 681-
685.
5. Vestbo J., Hurd S.S., Agusti A.G. et al: Global
strat-
egy for the diagnosis, management, and prevention o
f chronic
obstructive pulmonary disease: GOLD executive summ
ary.
Am. J. Respir. Crit. Care. Med. 2013; 187(4): 347-3
65.
6. Camm A.J., Lip G.Y., De Caterina R. et al. 2012
focused update of the ESC Guidelines for the manage
ment of
atrial fibrillation: an update of the 2010 ESC Guid
elines for
the management of atrial fibrillation. Developed wi
th the spe-
cial contribution of the European Heart Rhyt hm Ass
ociation.
Eur. Heart. J. 2012; 33(21): 2719-2747.
7. Miller M.R., Hankinson J., Brusasco V. et al. St
an-
dardisation of spirometry. The European respiratory
journal.
2005; 26(2): 319-338.
8. Lang R.M., Bierig M., Devereux R.B. et al. Rec-
ommendations f or chamber quantification: a report
from
the American Society of Echocardiography’s Guidelin
es and
Standards Committee and the Chamber Quantification
Writ-
ing Group, developed in conjunction with the Europe
an A s-
sociation of Echocardiography, a branch of the Euro
pean
Society of Cardiology. Journal of the American Soci
ety of
Echocardiography. 2005; 18(12): 1440-1463.
9. Mak J.C., Chan-Yeung M.M., Ho S.P. et al. Elevat
-
ed plasma TGF-
E
1 levels in patients with chronic obstruc-
tive pulmonary disease. Respiratory medicine. 2009;
103(7):
1083-1089.
32
Клинический вестник, 1–2016
Кремлевская медицина
10. Hodge S., Hodge G., Reynolds P. et al. Increase
d
production of TGF-
E
and apoptosis of T lymphoc ytes iso-
lated from peripheral blood in COPD. American Journ
al of
Physiology-Lung Cellular and Molecular Physiology.
2003;
285(2): L492-L499.
11. Behnes M., Hoffmann U., Lang S. et al. Transfor
m-
ing growth factor beta 1 (TGF-beta 1) in atrial fib
rillation
and acute congestive heart failure. Clinical resear
ch in cardi-
ology : official journal of the German Cardiac Soci
ety. 2011;
100(4): 335-342.
12. Li X., Ma C., Dong J. et al. The fibrosis and a
trial
fibrillation: is the transforming growth factor-bet
a 1 a candi-
date etiology of atrial fibrillation. Medical hypot
heses. 2008;
70(2): 317-319.
13. Cao H., Zhou Q., Lan R. et al. A Functional Pol
y-
morphism C-509T in TGFbeta-1 Promoter Contributes t
o
Susce ptibility and Prognosis of Lone Atrial Fibril
lation in
Chinese Population. PloS one. 2014; 9(11): e112912.
14. Zheng W., Yan C., Wang X. et al. The TGFB1 Func
-
tional Polymorphi sm rs1800469 and Susceptibility t
o Atrial
Fibrillation in Two Chinese Han Populations. PloS on
e.
2013.
15. Smolonska J., Wijmenga C., Postma D.S., Boezen
H.M.: Meta-analyses on suspected chronic obstructiv
e pul-
monary disease genes: a summary of 20 years’ resea
rch.
American journal of respiratory and critical care m
edicine.
2009; 180(7): 618-631